Skip to main content
Beverly Mitchell, MD, Oncology, Palo Alto, CA, Stanford Health Care

BeverlyShriverMitchellMD

Oncology • Palo Alto, CA

Hematologic Oncology

Professor, Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Mitchell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mitchell's full profile

Already have an account?

Education & Training

  • University of Michigan Health System
    University of Michigan Health SystemResidency, Internal Medicine, 1976 - 1977
  • University of Michigan Health System
    University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 1977
  • University of Washington
    University of WashingtonResidency, Internal Medicine, 1970 - 1973
  • University of Washington School of Medicine
    University of Washington School of MedicineInternship, Transitional Year, 1969 - 1970
  • Harvard Medical School
    Harvard Medical SchoolClass of 1969

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2006 - 2025
  • NC State Medical License
    NC State Medical License 1992 - 2021
  • MI State Medical License
    MI State Medical License 1975 - 1992
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Join now to see all

Publications & Presentations

PubMed

Press Mentions

  • ASH Presents Honorific Awards, Immunotherapy Researchers Receive Nobel Prize in Medicine, and More
    ASH Presents Honorific Awards, Immunotherapy Researchers Receive Nobel Prize in Medicine, and MoreDecember 1st, 2018
  • Steven Artandi Selected as New Director of Stanford Cancer Institute
    Steven Artandi Selected as New Director of Stanford Cancer InstituteOctober 23rd, 2018
  • Steven Artandi Tapped to Lead Stanford Cancer Institute
    Steven Artandi Tapped to Lead Stanford Cancer InstituteOctober 1st, 2018
  • Join now to see all

Grant Support

  • Project Senior LeadersNational Cancer Institute2011
  • Planning And EvaluationNational Cancer Institute2011
  • Developmental FundsNational Cancer Institute2011
  • Stanford University Cancer CenterNational Cancer Institute2008–2011
  • Cancer Stem Cells And Radiotherapy: New Approaches To RadiosensitizationNational Cancer Institute2009–2010
  • 2009 Aaci Annual MeetingNational Cancer Institute2009
  • Core--Protocol-Specific ResearchNational Cancer Institute2005–2009
  • Role Of Hpso4 In Double Strand Break RepairNational Institute Of General Medical Sciences2007
  • Inosine Monophosphate Dehydrogenase: Regulation And FunctionNational Cancer Institute2006–2007
  • Role Of Hpso$ In Double Strand Break RepairNational Institute Of General Medical Sciences2006
  • Role Of Hpso$ In Double Strand Break RepairNational Institute Of General Medical Sciences2005
  • Inosine Monophosphate Dehydrogenase: Regulation And FunctionNational Cancer Institute2004–2005
  • Role Of Hpso4 In Double Strand Break RepairNational Institute Of General Medical Sciences2004
  • Research Fellowships In Hematology/OncologyNational Heart, Lung, And Blood Institute1996–2004
  • Nucleoside And Nucleotide Metabolizing EnzymesNational Cancer Institute1995–2004
  • Inosine Monophosphate Dehydrogenase: Regulation/FunctionNational Cancer Institute2003
  • Refractory Hematologic Malignancies (Compound 506)National Center For Research Resources1999–2002
  • Inosine Monophosphate Dehydrogenase--Reg And FunctionNational Cancer Institute1998–2002
  • Study Of 506U78 In Patients With Refractory Hematologic CancerNational Center For Research Resources1998–1999
  • Phase 1 Study--Refractory Hematologic Malignancies (Compound 506)National Center For Research Resources1996–1997
  • IMP Dehydrogenase--Regulation And FunctionNational Cancer Institute1994–1997
  • Icn001--Phase II Study Of Patients With CML In Blast Crisis Treated W/ TiazofurinNational Center For Research Resources1996
  • Terminal Transferase In Mammalian Hemopoietic TissueNational Cancer Institute1994–1995
  • Inhibitors Of Purine Nucleoside PhosphorylaseNational Cancer Institute1991–1994
  • Overproduction Of Adenosine Deaminase In ErythrocytesNational Institute Of Allergy And Infectious Diseases1991–1993
  • Overproduction Of Adenosine Deaminase In ErythrocytesNational Institute Of Allergy And Infectious Diseases1986–1991
  • Inhibitors Of Purine Nucleoside PhosphorylaseNational Cancer Institute1985–1991

Professional Memberships

Hospital Affiliations

Dr. Beverly Mitchell, Dr. Beverly Mitchell, MD, Dr. B Mitchell, Dr. Beverly Shriver Mitchell